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Abstract
Background: Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, and its role in cancer
biology has been widely studied. Many cancer therapies target angiogenesis, with a focus being on VEGF-mediated
signaling such as antibodies to VEGF. However, it is difficult to predict the effects of VEGF-neutralizing agents. We
have developed a whole-body model of VEGF kinetics and transport under pathological conditions (in the
presence of breast tumor). The model includes two major VEGF isoforms VEGF121 and VEGF165, receptors VEGFR1,
VEGFR2 and co-receptors Neuropilin-1 and Neuropilin-2. We have added receptors on parenchymal cells (muscle
fibers and tumor cells), and incorporated experimental data for the cell surface density of receptors on the
endothelial cells, myocytes, and tumor cells. The model is applied to investigate the action of VEGF-neutralizing
agents (called “anti-VEGF”) in the treatment of cancer.
Results: Through a sensitivity study, we examine how model parameters influence the level of free VEGF in the
tumor, a measure of the response to VEGF-neutralizing drugs. We investigate the effects of systemic properties
such as microvascular permeability and lymphatic flow, and of drug characteristics such as the clearance rate and
binding affinity. We predict that increasing microvascular permeability in the tumor above 10
-5 cm/s elicits the
undesired effect of increasing tumor interstitial VEGF concentration beyond even the baseline level. We also
examine the impact of the tumor microenvironment, including receptor expression and internalization, as well as
VEGF secretion. We find that following anti-VEGF treatment, the concentration of free VEGF in the tumor can vary
between 7 and 233 pM, with a dependence on both the density of VEGF receptors and co-receptors and the rate
of neuropilin internalization on tumor cells. Finally, we predict that free VEGF in the tumor is reduced following
anti-VEGF treatment when VEGF121 comprises at least 25% of the VEGF secreted by tumor cells.
Conclusions: This study explores the optimal drug characteristics required for an anti-VEGF agent to have a
therapeutic effect and the tumor-specific properties that influence the response to therapy. Our model provides a
framework for investigating the use of VEGF-neutralizing drugs for personalized medicine treatment strategies.
Background
Angiogenesis, the formation of new capillaries from pre-
existing blood vessels, is a tightly regulated biological
process and is involved in normal physiological function
as well as in pathological conditions. Angiogenesis
occurs in embryos during organ growth and develop-
ment [1]. In adults, angiogenesis is essential for condi-
tions requiring an increase in blood and oxygen supply,
including reproduction, physiological repair (e.g., wound
and tissue healing), and exercise [2,3]. In addition to its
relevance in physiological conditions, angiogenesis has a
prominent role in diseases such as preeclampsia,
ischemic heart disease, and cancer. Neovascularization
allows for cancer development, tumor growth, and
metastasis whereby the tumor elicits the formation of
capillaries to obtain its own blood supply [4].
Vascular endothelial growth factor (VEGF) is a potent
regulator of angiogenesis, and its role in cancer biology
has been widely studied. Clinically, cancer patients exhi-
bit increased VEGF levels [5]¸ although this finding
remains controversial [6], and vascularization in tumors
shows marked differences from physiological vessel
architecture: increased leakiness and tortuosity,
decreased pericyte coverage, and abnormal organization
[7,8]. For these reasons, many cancer therapies target
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VEGF-mediated signaling in the form of antibodies to
VEGF and its receptors, small molecule tyrosine kinase
inhibitors, and peptides [9-11].
The human VEGF family includes five ligands (VEGF-
A through -D and placental growth factor, PlGF), three
receptors (VEGFR1, VEGFR2, and VEGFR3), and two
co-receptors, neuropilins (NRP1 and NRP2). VEGF
binding to its receptors regulates vessel permeability
[12] and expression of matrix metalloproteinases [13],
involved in capillary sprout formation. Angiogenesis
involves numerous molecular species and includes
events that occur at the molecular, cellular, and tissue
levels in sequence and in parallel. This complexity lends
the process of angiogenesis to systems biology
approaches [14,15]. Computational modeling, in particu-
lar, is useful in understanding angiogenesis and provides
a framework to test biological hypotheses [16]. Addi-
tionally, the models can aid in the development and
optimization of therapies targeting this process [16-19].
Our laboratory previously developed a whole-body
model of VEGF kinetic and transport necessary for
building models of VEGF-mediated angiogenesis [20,21].
One of the models predicts the distribution of VEGF in
the body upon administration of the anti-VEGF recom-
binant humanized monoclonal antibody bevacizumab
[21]. The findings suggest that anti-VEGF agents act to
deplete tumor VEGF rather than blood (plasma) VEGF
because the blood VEGF was predicted to decrease tran-
siently and then increase above the baseline pre-treat-
ment level. In the present study, we extend the previous
computational model to include receptors on parenchy-
mal cells. Our previous models were limited by a lack of
quantitative measurements of cell surface receptor den-
s i t i e s .T h e r e f o r e ,u s i n gq u a n titative flow cytometry, we
have determined the density of VEGF receptors and co-
receptors on the surface of endothelial cells, skeletal
muscle myocytes, and tumor cells, and incorporated
these key parameters into the current model. Addition-
ally, we have included VEGF degradation and have uti-
lized published in vitro data to establish a baseline for
the rate of VEGF secretion by tumor cells. These signifi-
cant model additions provide a physiologically-based
computational framework to study VEGF kinetics and
transport.
We utilize the model to investigate how systemic
properties, drug characteristics, and properties of the
tumor microenvironment influence the response to the
anti-VEGF agent. The simulations show that the level of
VEGF in the tumor interstitium can decrease or, para-
doxically, increase beyond even the baseline pre-treat-
ment level as a result of anti-VEGF administration
depending on the values of parameters. Importantly, we
predict the ranges of parameter values which elicit the
undesired effect of increasing tumor interstitial VEGF
concentration. Thus, our model can be used to predict
the optimal drug and tumor properties for which an
anti-VEGF agent may have a therapeutic effect.
Methods
Computational methods
Computational Model
Here, we summarize the features of the model and
describe significant enhancements from previous mod-
els: the presence of VEGF receptors on parenchymal
cells, incorporating experimental quantification of VEGF
receptor expression, and the degradation of VEGF in
the tissue compartments; the degradation of VEGF in
the blood compartment is included in the clearance
term. The complete set of 67 ordinary differential equa-
tions (ODEs) is given in Additional file 1, and prior
models created by our laboratory are fully detailed in
our previous papers [20,21].
The model is comprised of three compartments: nor-
mal tissue ("normal compartment”, represented by skele-
tal muscle), the vascular system ("blood compartment”),
and diseased tissue ("tumor compartment”). As a start-
ing point, we modeled a breast tumor measuring 4 cm
in diameter; however, the tumor compartment can be
adapted to represent any solid tumor in the body,
including metastatic disease. Thus, the setting mimics
neoadjuvant therapy when the agent is administered
prior to surgical rescission of the tumor; alternatively,
the tumor may represent a metastatic growth.
The tissue is divided into parenchymal cells, capil-
laries, and interstitial space. Parenchymal cells include
muscle fibers in the normal compartment and tumor
cells in the tumor compartment. The interstitial space is
subdivided into the extracellular matrix (ECM), the
endothelial cell basement membrane (EBM), and par-
enchymal cell basement membrane (PBM). The two
VEGF isoforms included in the model, VEGF121 and
VEGF165, are secreted from the parenchymal cells and
can diffuse in the interstitium. VEGF165 contains a
heparin-binding domain that enables this isoform to
bind reversibly to glycosaminoglycan (GAG) chains in
the ECM and basement membranes; in contrast,
VEGF121 can diffuse freely in the interstitial fluid. A
portion of the interstitial space is unavailable to VEGF
because of the volume occupied by the extracellular
matrix molecules and closed pores in the matrix. There-
fore, we specify UAV, the available fluid volume, as UAV
= KAV × U,w h e r eKAV is the available volume fraction,
and U is the tissue volume.
The molecular interactions of VEGF and its receptors
are illustrated in Figure 1. This model includes the pre-
sence of VEGF receptors VEGFR1 and VEGFR2, as well as
co-receptors neuropilins NRP1 and NRP2. VEGF binds to
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lial surfaces, on muscle fibers, and on tumor cells.
VEGFR1, VEGFR2, and NRP1 are all present on endothe-
lial cells. Muscle fibers may express very low levels of
VEGFR1 and VEGFR2; however, the density of NRP1 is
relatively high. Additionally, tumor cells express both
N R P 1a n dN R P 2[ 2 2 ]a sw e l la sV E G F R 1a n dV E G F R 2 .
Ligated and unligated receptors are internalized; however,
the total number of receptors of each type is assumed to
be constant at any given time, i.e., as receptors are interna-
lized, an equal number of unligated receptors is instanta-
neously inserted into the cell membrane. This assumption
can be easily relaxed when information about receptor
dynamics becomes available. Intercompartment transport
of free VEGF includes vascular permeability and lymph
flow. VEGF intravasates and extravasates via transendothe-
lial macromolecular permeability. Additionally, VEGF can
flow from the normal tissue into the blood via lymphatic
drainage. However, it is assumed that tumor lymphatics
are non-functioning, based on experimental evidence
[23,24]. Lastly, the ligand can be removed from the blood
via clearance.
In addition to disappearing via receptor-mediated
internalization and blood clearance, VEGF is subject to
proteolysis by plasmin and matrix metalloproteinases.
Therefore, we have included an intrinsic protein degra-
dation term for VEGF, which has not appeared in our
previous models. Based on experimental measurements
for the half-life of VEGF [25-27], we have set the degra-
dation rate constant to be 1.93 × 10
-4 s
-1, corresponding
to a half-life of 60 minutes.
The model includes an anti-VEGF agent that is
added to the blood compartment once steady-state is
reached, simulating an intravenous injection. The anti-
V E G Fb i n d st ob o t hV E G Fi s o f o r m si na l lc o m p a r t -
ments to form the VEGF/anti-VEGF complex. Free
anti-VEGF and the complex can be transported via
microvascular permeability and lymphatic drainage,
and can be cleared from the blood. Administration of
the anti-VEGF occurs via infusion for 90 minutes at a
dose of 10 mg/kg. In this study, we simulate a 70-kg
patient; therefore, the rate at which the anti-VEGF is
administered is 7.78 mg/min (denoted as qA in equa-
tion S.38 of Additional file 1).
Figure 1 Molecular interactions. The binding interactions between VEGF, surface receptors, extracellular matrix and basement membranes.
VEGF165 binds to VEGFR1, VEGFR2, and co-receptors NRP1 and NRP2. VEGF165 also binds to glycosaminoglycan (GAG) chains in the extracellular
matrix and basement membranes. VEGF121 binds to VEGFR1 and VEGFR2, but is unable to bind to NRPs. The molecular interactions between the
VEGF isoforms and NRP1 or NRP2 are identical, but are governed by different kinetic parameters. The anti-VEGF agent binds to both isoforms.
The receptors and co-receptors are inserted and internalized at the cell surface.
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The model is described by 67 non-linear ordinary differ-
ential equations: 24 for the normal compartments, 16
for the blood, and 27 for the tumor compartment.
These equations were implemented in MATLAB
(v7.11.0.584 R2010b, Mathworks) using the SimBiology
toolbox. The steady-state and dynamic solutions were
calculated using the Sundials solver. An absolute toler-
ance of 10
-9 was used, and the relative tolerance was set
at 10
-20.
Model parameters
The geometric parameters of the compartments, the
kinetic constants governing the molecular interactions,
and the initial concentrations are the same as those
used in our previous model [21], with the exception of
the receptor densities and degradation. In the present
model, we include in vivo and in vitro quantification of
VEGF receptors (experimental methods based on quan-
titative flow cytometry are described below), and the
receptor densities, presented as dimerized receptors, are
Table 1 Receptor densities
Measured parameters Model parameters
Value Unit Value Unit
VEGFR1
Luminal EC (normal) 550 rec/EC 1.21 × 10
-1 pmol/cm
3 tissue
Abluminal EC (normal) 550 rec/EC 9.86 × 10
-3 pmol/cm
3 tissue
Luminal EC (diseased) 3,750 rec/EC 4.38 × 10
-4 pmol/cm
3 tissue
Abluminal EC (diseased) 3,750 rec/EC 6.54 × 10
-2 pmol/cm
3 tissue
Myocytes 0 rec/myocyte 0 pmol/cm
3 tissue
Tumor cells 1,100 rec/tumor cell 2.81 × 10
-1 pmol/cm
3 tissue
VEGFR2
Luminal EC (normal) 350 rec/EC 7.70 × 10
-2 pmol/cm
3 tissue
Abluminal EC (normal) 350 rec/EC 6.28 × 10
-3 pmol/cm
3 tissue
Luminal EC (diseased) 300 rec/EC 3.51 × 10
-5 pmol/cm
3 tissue
Abluminal EC (diseased) 300 rec/EC 5.23 × 10
-3 pmol/cm
3 tissue
Myocytes 0 rec/myocyte 0 pmol/cm
3 tissue
Tumor cells 550 rec/tumor cell 1.41 × 10
-1 pmol/cm
3 tissue
NRP1
Luminal EC (normal) 17,500 rec/EC 3.74 pmol/cm
3 tissue
Abluminal EC (normal) 17,500 rec/EC 3.05 × 10
-1 pmol/cm
3 tissue
Luminal EC (diseased) 20,000
† rec/EC 2.34 × 10
-3 pmol/cm
3 tissue
Abluminal EC (diseased) 20,000
† rec/EC 3.49 × 10
-1 pmol/cm
3 tissue
Myocytes 34,500 rec/myocyte 2.06 pmol/cm
3 tissue
Tumor cells 39,500 rec/tumor cell 1.01 × 10
1 pmol/cm
3 tissue
NRP2
Luminal EC (normal) 0 rec/EC 0 pmol/cm
3 tissue
Abluminal EC (normal) 0 rec/EC 0 pmol/cm
3 tissue
Luminal EC (diseased) 0 rec/EC 0 pmol/cm
3 tissue
Abluminal EC (diseased) 0 rec/EC 0 pmol/cm
3 tissue
Myocytes 0 rec/myocyte 0 pmol/cm
3 tissue
Tumor cells 39,500
‡ rec/tumor cell 1.02 × 10
1 pmol/cm
3 tissue
EC = endothelial cell; rec = receptors
† Extrapolated from receptor density on normal ECs, accounting for different cell surface areas
‡No NRP2 quantification available; assumed to be the same as NRP1 on tumor cells
Conversions of receptor densities to tissue concentrations:
Abluminal EC receptors (normal): 1.79 × 10
-5 (pmol/cm
3 tissue)/(rec/EC);
Luminal EC receptors (normal): 2.20 × 10
-4 (pmol/cm
3 tissue)/(rec/EC);
Abluminal EC receptors (diseased): 1.74 × 10
-5 (pmol/cm
3 tissue)/(rec/EC);
Luminal EC receptors (diseased): 1.17 × 10
-7 (pmol/cm
3 tissue)/(rec/EC);
Myocyte receptors: 5.96 × 10
-5 (pmol/cm
3 tissue)/(rec/myocyte);
Tumor receptors: 2.55 × 10
-4 (pmol/cm
3 tissue)/(rec/tumor cell);
Myocyte receptor densities are expressed per myonuclear domain
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determine the effect of varying the receptor density,
thus these values provide a starting point for our analy-
sis. We are particularly interested in the effect of neuro-
pilin density, as only in vitro data are available for the
expression of NRP1, and the level of NRP2 expression
has not been quantified.
Experimental methods
Cell culture
Human umbilical vein endothelial cells (HUVEC), human
dermal microvascular endothelial cells (MEC), and
human skeletal muscle cells from gastrocnemius (SkM)
were acquired from individual donors (Lonza, Walkers-
ville, MD and Stem Cell Technologies, Vancouver,
Canada). The endothelial cells were maintained in
Endothelial Cell Growth Medium-2 (EGM-2), supple-
mented by the EGM-2 SingleQuot Kit for HUVECs, or
supplemented by the EGM-2 Microvascular SingleQuot
Kit for MECs (Lonza). The skeletal muscle cells were
maintained in Skeletal Muscle Cell Growth Medium
(SkGM) supplemented by the SkGM BulletKit (Lonza).
Breast cancer cells MDA-MB-231were kindly provided
by Dr. Zaver M. Bhujwalla (Johns Hopkins University)
with the following details about the cell line: MDA-MB-
231 breast cancer cells were purchased from the Ameri-
can Type Culture Collection (ATCC) and used within 6
months of obtaining them from ATCC; the cell line was
tested and authenticated by ATCC by two independent
m e t h o d s ;t h eA T C Cc y t o c h r o m eCo x i d a s eIP C Ra s s a y
and short tandem repeat profiling using multiplex PCR.
MDA-MB-231 cells were maintained in DMEM contain-
ing 10% fetal bovine serum (Invitrogen) and 1% Penicil-
lin-Streptomycin (Invitrogen). Cells were grown at 37°C
in 95% air, 5% CO2. Cells were grown to confluence
before use and primary cells were only used through pas-
sage 6. For routine cell culture, cells were detached from
flasks using 0.25% TrypLE (Invitrogen, Carlsbad, CA).
Tumor xenograft
Animal protocols were approved by the Institutional
Care and Use Committee at the Johns Hopkins Medical
Institutions (JHMI). MDA-MB-231 cells were disso-
ciated from flasks with TrypLE (Invitrogen, Carlsbad,
CA), washed twice in PBS, and resuspended in Dulbec-
co’s Modified Eagle Medium. Mice were anesthetized
using 0.125 mg Acepromazine and 12.5 mg Ketamine.
Subsequently, 2 million cells/100-μLs o l u t i o nw e r e
injected into each side of the mammary fat pad of 7
week-old, female, athymic NCr-nu/nu mice. Tumors
were grown for 23 days, to an average size of 620 ± 170
mm
3, as calculated by measuring the long (l)a n ds h o r t
(s) axis of the ellipsoid tumor with a caliper and apply-
ing the following equation: V = s
2*l/2.
Endothelial cell isolation from tissue
Tissue was digested as previously described [28-30].
Briefly, tissue was minced into 1 mm sections and
added to freshly prepared 0.2% collagenase type IV fil-
tered (Worthington Biochemical Corporation, Lake-
wood, NJ), which had been reconstituted in Hanks
Balanced Salt Solution without calcium and without
magnesium. The tissue was digested for 30 min at 37°C
with intermittent vortexing then passed through a 70
μm strainer (BD). Cells were centrifuged at 300 × g for
5 minutes and re-suspended in 30 mL of 0.2 μm filtered
Isolation Buffer containing PBS without calcium and
magnesium (Invitrogen), 2 mM EDTA (Mediatech), and
0.1% BSA (Sigma). Endothelial cells were isolated from
the cell suspension using DSB-X (Invitrogen) biotiny-
lated mouse CD31 antibody (eBioscience and BD
Bioscience, San Diego, CA) and FlowComp Dynabeads
(Invitrogen) according to the manufacturers’
instructions.
I nt h i ss t u d yw eo n l yq u a n t i f yV E G F R 1a n dV E G F R 2 ,
because the levels of these receptors are unchanged by
the collagenase IV tissue dissociation; however, NRP1 is
not quantified, because its surface levels are significantly
decreased following collagenase IV treatment, due to the
presence of trypsin [31]. Cell staining and flow cytome-
try were performed as we have previously described
[31].
Results
Tumor interstitial free VEGF is sensitive to kinetic
parameters for NRP2 molecular interactions
The current model includes NRP1 on muscle cells, and
both NRP1 and NRP2 on tumor cells, which have not
appeared in previous models. Given the range of values
for the binding constant for NRP2 and VEGF165 and the
lack of data for the coupling rate of NRP2 and VEGFR1
or VEGFR2, we performed a sensitivity study to
Table 2 Kinetic constants for NRP2 interactions
Measured parameters Model parameters
Value Unit Value Unit
kon,V165,N 2 10
6 M
-1 s
-1 1.92 × 10
-3 (pmol/cm
3 tissue)
-1 s
-1
kc,V165 R2,N 2 3.1 × 10
13 (mol/cm
2)
-1 s
-1 2.02 × 10
-2 (pmol/cm
3 tissue)
-1 s
-1
kc,V165 N 2,R2 10
14 (mol/cm
2)
-1 s
-1 7.06 × 10
-2 (pmol/cm
3 tissue)
-1 s
-1
kc,R1,N 2 10
14 (mol/cm
2)
-1 s
-1 7.06 × 10
-2 (pmol/cm
3 tissue)
-1 s
-1
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2). In the sensitivity study, we vary each of these para-
meters individually over eight orders of magnitude and
use the model to predict the steady-state free VEGF
levels in the normal, blood, and tumor compartments.
We calculate the percent change in free VEGF for the
range of parameter values examined to determine how
sensitive the model predictions are to the parameters of
interest. We used the values of the kinetic parameters
for NRP1 interactions as the starting baseline value (cir-
cles). Tumor VEGF is sensitive to the association rate
for NRP2 and VEGF165, kon,V165,N2 (varies 22% for the
range of parameter values examined), and we set this
value to be 10
6 M
-1 s
-1, which is in the range of avail-
able experimental data [32,33] (squares and triangles).
We assumed the dissociation rate to be the same as
VEGF165 dissociating from NRP1 (10
-3 s
-1), resulting in
a Kd of 1 nM. We used the kinetic constants for NRP1
for kc,V165R2,N2 and kc,R1,N2, as the steady state concen-
trations are not sensitive to these parameters (less than
1% change in the free VEGF in all compartments).
Although tumor free VEGF varies 18% across the range
of values examined for kc,V165N2,R2, there is little experi-
mental data available for this kinetic constant. There-
fore, we set the value for the parameter to be the same
as that for NRP1. All of the kinetic parameters govern-
ing the interactions of NRP2 are listed in Table 2.
The distribution and density of VEGF receptors on
endothelial and parenchymal cells significantly alters free
VEGF distributions in the normal tissue and tumor
We have quantified the effect of utilizing experimental
data for the density of VEGF receptors, accounting for
VEGF receptors on both the abluminal and luminal
endothelial surface, and including receptor expression
on parenchymal cells (NRP1 on muscle fibers and
VEGFR1, VEGFR2, NRP1, and NRP2 on tumor cells), as
shown in Figure 2. In all cases, the plasma free VEGF
concentration is fixed at 4.5 pM by readjusting the
VEGF secretion rate. We have not included VEGF
degradation in these simulations, in order to provide a
fair comparison to previous models. We first compared
Figure 2 Effect of model parameters. The concentration of predicted free VEGF in the interstitium is sensitive to the presence and density of
receptors on abluminal and luminal endothelial surfaces, and on myocytes and tumor cells. Baseline Model 1 is based on [20], and Baseline
Model 2 is based on [34]. In the baseline models, receptor density is assumed to be: 10,000 VEGFR1, 10,000 VEGFR2, and 100,000 NRP1
molecules/endothelial cell. Experimental receptor density is based on in vitro in human cells using quantitative flow cytometry [31] and in vivo
quantification in mouse skeletal muscle and tumor xenografts using the same technique. In each simulation, VEGF secretion is tuned to maintain
blood free VEGF at 4.5 pM. Simulation cases are as follows: A, VEGFR1, VEGFR2, and NRP1 present on abluminal endothelial surface with assumed
receptor density. B, VEGFR1, VEGFR2, and NRP1 present on abluminal endothelial surface with experimental receptor density. C, VEGFR1, VEGFR2,
and NRP1 evenly distributed on abluminal and luminal endothelial surface with assumed receptor density. D, VEGFR1, VEGFR2, and NRP1 evenly
distributed on abluminal and luminal endothelial surface with experimental receptor density. Cases E through K build upon the previous case by
sequentially refining the model: E, Addition of NRP1 on myocytes. F, Addition of VEGFR1 on tumor cells. G, Addition of VEGFR2 present on
tumor cells. H, Addition of NRP1 on tumor cells. I, Addition of NRP2 on tumor cells. J, Incorporation of VEGF degradation in normal tissue and
tumor. K, Incorporation of experimental data for VEGF secretion by tumor cells (Current Model).
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et al. [20] (referred to as Baseline Model 1), where
VEGF receptors are expressed solely on the abluminal
endothelial surface, and receptor density is assumed to
be 10,000 VEGFR1, 10,000 VEGFR2, and 100,000 NRP1
molecules/endothelial cell. Experimental measurements
of VEGF receptor expression are described in the Meth-
ods section, and the values are listed in Table 1. Incor-
poration of experimental data for the density of VEGF
receptors results in an increase of 1% and 15% for free
VEGF in the normal tissue and tumor, respectively, as
compared to Baseline Model 1 (Figure 2, cases A and
B). Thus, experimental quantification of VEGF receptors
has a slight effect on the distribution of VEGF in the
body, when considering only abluminal localization of
receptors.
We next examined how the inclusion of luminal
receptors impacts free VEGF in the body. Here, we
compare to Baseline Model 2, based on a model by Ste-
fanini and coworkers [34]. In Baseline Model 2, the
receptor density is still assumed to be VEGFR1 =
10,000, VEGFR2 = 10,000, and NRP1 = 100,000 recep-
tors/endothelial cell; however, receptors are now evenly
distributed on the abluminal and luminal endothelial
surface (i.e., for VEGFR1, there are 5,000 receptors on
the luminal surface of the endothelial cells and 5,000
abluminal receptors). The equal distribution of receptors
on the endothelial cell surface significantly increases free
VEGF in the normal tissue and tumor (Baseline Model 1
compared to Baseline Model 2, i.e., Figure 2, case A
compared to Figure 2, case C); free VEGF in the normal
tissue increases more than 15-fold, while tumor VEGF
increases almost 6-fold. This increase can be attributed
to having to increase VEGF secretion in normal tissue
and tumor in order to maintain 4.5 pM free VEGF in
the plasma. Upon utilizing experimental data for VEGF
receptor density and accounting for even distribution of
receptors on the abluminal and luminal endothelial sur-
faces (Figure 2, case D), we found that the free VEGF in
both the normal tissue and tumor decreased 3.2- and
1.1-fold, respectively, as compared to Baseline Model 2.
Lastly, we investigated the effect of parenchymal
receptors on the concentration of free VEGF. We
sequentially added VEGF receptors to different cell
types and predicted the concentration of free VEGF in
the normal tissue and tumor (Figure 2, cases E through
I). In each case, VEGF secretion was tuned such that
the concentration of free VEGF in the plasma was 4.5
pM. When NRP1 co-receptors are present on myocytes
in the normal compartment, a significant change in the
concentration of free VEGF in the normal tissue and
tumor is observed (Figure 2, case E compared to Base-
line Model 2). Free VEGF in the normal tissue is
reduced almost 6-fold, since VEGF bound to the
receptors on myocytes can be internalized, acting as a
sink for VEGF. Conversely, tumor VEGF increases 1.3-
fold. This is because extrapolation from in vitro experi-
ments estimates the number of NRP1 co-receptors on
the tumor endothelium to be 39,500 molecules/cell,
compared to the value of 100,000 molecules/cell used in
Baseline Model 2, leading to more unbound VEGF. As
the density of VEGF receptors on tumor cells is adjusted
to fully reflect experimental data by sequentially adding
receptors, free VEGF in the tumor decreases 63-fold
(Figure 2, case I) compared to Baseline Model 2 (Figure
2, case C). This analysis demonstrates the importance of
having accurate estimates of receptor density, as the
model is sensitive to these parameters.
The rate of VEGF secretion and the VEGF isoform
secretion ratio VEGF165:VEGF121 in the tumor affect the
distribution of free VEGF in the body
An important model parameter is the rate at which
VEGF is secreted by muscle fibers in the normal tissue
and tumor cells in the tumor compartment, which influ-
ences the level of free VEGF in the body. In previous
models, we assumed that the parenchymal cells in the
normal tissue and tumor secrete the same amount of
VEGF. However, in the present study, we have incorpo-
rated in vitro measurements of the rate of VEGF secre-
tion from cells from various human tumor cell lines
[35-38]. Given the wide range of values for VEGF secre-
tion (0.04 to 2.65 molecules/cell/s), we estimated the
effect of the tumor VEGF secretion rate on steady-state
f r e eV E G Fi nt h eb o d y( F i g u r e3 A ) .W h e nt h er a t eo f
VEGF secreted by tumor cells is varied from 0 up to 3
molecules/cell/s, free VEGF in the tumor increases from
0.06 pM to 2 nM, an increase of more than four orders
of magnitude. Conversely, free VEGF in the normal tis-
sue and blood increase by 0.1% and 9%, respectively.
These results show that varying the rate of VEGF
secreted by tumor cells is a means of tuning the level of
free VEGF in the tumor, leaving free VEGF in the nor-
mal tissue and blood largely unaffected. In this way, we
are able to set the tumor secretion rate in order to
achieve a certain level of free VEGF in the tumor. A
detailed comparison to experimental data for tumor
VEGF concentration is presented in Additional file 3.
Briefly, we utilize a meta-analysis of VEGF content in
cancer patients for various tumor types performed by
Kut et al. [5]; the weighted average of intracellular and
extracellular tumor VEGF for all cancer studies was
reported to be 334 pg/mg protein, with a significant var-
iation between different studies. This value represents
the sum of the free and bound VEGF. Converting to the
concentration of free VEGF requires the fraction of free:
total VEGF, which depends of the isoform secretion
ratio as well as the density of ECM binding sites and
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ple, at 2% of free VEGF as a percent of total (free and
bound), the above experimental value is equivalent to 82
pM for the free interstitial VEGF concentration; at 6%
the concentration of free VEGF is 245 pM. Thus, the
experimental data suggest that the interstitial tumor
VEGF concentration levels are 10-60 times higher than
the plasma concentration. Methods of isolating tumor
interstitial fluid (TIF) exist that should allow measure-
ments of protein concentration [39]; however, there is a
lack of direct quantitative measurements of free VEGF
in the TIF or in normal tissues such as skeletal muscle.
A sab a s e l i n ev a l u e ,w eh a v es e tt h er a t eo fV E G F
secreted by tumor cells to be 0.56 molecules/cell/s (the
average of the available experimental data), and this
value is used in all simulations presented below. When
VEGF is secreted at this rate, and VEGF degradation in
the normal tissue and tumor compartments is included,
free VEGF in the tumor is predicted to be 73 pM (Fig-
ure 2, case K).
In addition to the absolute rate at which VEGF is
secreted by tumor cells, it is also important to consider
the relative secretion rate of the VEGF isoforms. A com-
pilation of qualitative information regarding the distri-
bution of VEGF in tumor tissue reveals that VEGF121 is
expressed at similar mRNA levels as, and in some cases
at higher levels than, VEGF165 for several tumor types
[40-44]. This is in contrast to skeletal muscle where
VEGF165 expression is predominant [45,46]. Although
these data are for mRNA expression, they represent the
only quantitative data available for the relative levels of
VEGF isoforms in tissue.
In order to understand the impact of the expression of
VEGF isoforms, the isoform secretion ratio VEGF165:
VEGF121 in the tumor was varied between 100%:0% to
0%:100% from the previous value of 92%:8%, while keep-
ing the total VEGF secretion rate constant at 0.56 mole-
cules/cell/s. The isoform secretion ratio in normal tissue
remained at 92%:8%. As the relative amount of VEGF121
secreted by the tumor is increased from zero to 100%,
free VEGF in the tumor increases by 94% (Figure 3B).
This can be explained by examining the distribution of
VEGF. Since VEGF121 is unable to bind to GAG chains
in the extracellular matrix and basement membranes,
the percentage of matrix-bound VEGF decreases as
more VEGF121 is secreted (Figure 3C). Additionally, the
VEGF internalization influences the free VEGF level.
VEGF165 can bind directly to NRP1, and the VEGF165/
NRP1 complex can subsequently be internalized.
Because VEGF121 is unable to bind directly to NRP1,
this isoform does not undergo the same amount of
NRP1-mediated clearance, as compared to VEGF165.T o
better reflect experimental data, we set the isoform
secretion ratio VEGF165:VEGF121 in the tumor to be
50%:50% and use this value in all simulations presented
below.
Free VEGF is predicted to decrease in the normal and
tumor compartments and increase in the blood following
intravenous administration of an anti-VEGF agent
It has been shown experimentally that VEGF in the
blood plasma increases following anti-VEGF treatment
[47-50], and our previous model reproduces this
increase [21]. The model also predicts that free VEGF in
the tumor decreases and remains below baseline follow-
ing intravenous administration of anti-VEGF. This led
to the hypothesis that the anti-VEGF agent acts to
deplete VEGF from the tumor, rather than from the
Figure 3 Effect of tumor VEGF secretion. The rate of VEGF secreted by tumor cells and the tumor isoform secretion ratio VEGF165:VEGF121
induces whole-body changes in the distribution of VEGF. A, Effect of tumor VEGF secretion rate on the steady-state free VEGF concentration in
the body. Gray circles indicate the secretion rate used in the current model, 0.56 molecules/cell/s. B, Steady-state free VEGF concentration in the
body. Gray circles indicate the ratio used in the current model, VEGF165:VEGF121 = 50%:50% in the tumor. C, Distribution of free, receptor-, and
matrix-bound VEGF: black, unbound VEGF; light gray, receptor-bound VEGF; dark gray, VEGF bound to GAG chains in the extracellular matrix and
basement membranes.
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increase in blood plasma free VEGF following anti-
VEGF therapy; free VEGF in the blood is predicted to
transiently decrease and then increase 9.2-fold three
weeks following anti-VEGF treatment (Figure 4A). The
current model also supports the hypothesis that a conse-
quence of treatment with an anti-VEGF agent is a
depletion of VEGF in the tumor. Following administra-
tion of the anti-VEGF, the decrease of free VEGF in the
normal and tumor compartments is due to the forma-
tion of the VEGF/anti-VEGF complex (Additional file
4). Additionally, less VEGF is bound to its receptors and
sequestered in the matrix following treatment.
We have investigated the effects of various model
parameters on the distribution of free VEGF, free anti-
VEGF, and the VEGF/anti-VEGF complex in the body.
Specifically, we evaluated how systemic properties, drug
characteristics, and properties of the tumor microenvir-
onment influence the response to VEGF-neutralizing
drugs. As a measure of the response to anti-VEGF treat-
ment, we calculated the fold-change in tumor free
VEGF at three weeks following administration of the
anti-VEGF agent. The three-week time point was
selected because free VEGF concentration in the body is
not significantly different after multiple cycles where the
anti-VEGF is administered every three weeks. Therefore,
we simulate one cycle of anti-VEGF treatment and cal-
culate the fold-change as:
fold-change =
[VEGF]t=3weeks
[VEGF]t=0
(1)
The fold-change is a ratio that indicates whether free
VEGF increased (fold-change > 1), decreased (fold-
change < 1), or was unchanged (fold-change = 1) at a
specific time following an anti-VEGF treatment, com-
pared to the steady-state level prior to treatment. We
are particularly interested in understanding the
conditions for which free VEGF in the tumor decreases
following anti-VEGF treatment, which corresponds to a
fold-change in tumor VEGF less than one and is termed
a therapeutic effect. The fold-change in tumor VEGF is
0.6 for the set of parameter values used in the current
model.
We have performed a sensitivity study in order to
determine the conditions for which the anti-VEGF has a
therapeutic effect. The sensitivity study systematically
investigates the impact of individual model parameters
over the entire simulation period and allows us to quan-
tify the effect of these parameters on model outputs of
interest: the fold-change in tumor VEGF and the con-
centration profiles of VEGF, anti-VEGF, and the VEGF/
anti-VEGF complex. We have used the model to predict
the fold-change and concentration profiles for a range
of parameter values and compare to the model outputs
obtained when the initial, baseline value is used. The
results of the sensitivity study are presented below. For
each model parameter examined, we state the range of
values explored.
Varying systemic properties can alter VEGF distribution
throughout the body or in specific compartments and
can influence the response to anti-VEGF therapy
We examined the impact of varying microvascular per-
meability between the normal tissue or tumor and the
blood (kNB
p,V and kTB
p,V, respectively) and of varying lympha-
t i cd r a i n a g e( kL). The microvascular permeability to
VEGF between the normal tissue and blood was varied
from 4 × 10
-11 to 4 × 10
-5 cm/s. Increasing kNB
p,V had a
pronounced effect on the concentration of free VEGF in
the normal tissue and plasma prior to the anti-VEGF
injection (Figure 5A). As kNB
p,V increases, the steady-state
concentration of VEGF in the normal tissue decreases
prior treatment, and the fold-change in free VEGF con-
centration becomes approximately one (Figure 5A top
Figure 4 Whole-body changes in response to anti-VEGF treatment. Concentration profiles following a single intravenous injection of 10 mg/
kg anti-VEGF given at time 0. A, VEGF concentration. B, Anti-VEGF concentration. C, Concentration of the VEGF/anti-VEGF complex.
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p,V leads to an increase
in the concentration of free VEGF before and after anti-
VEGF treatment; however, the fold-change in free VEGF
in the blood remains greater than one for all values of
kNB
p,V examined (Figure 5A middle panel). Varying kNB
p,V
does not substantially influence free VEGF in the tumor
(Figure 5A bottom panel).
The effects of varying microvascular permeability to
VEGF between the tumor and blood are confined to the
tumor compartment (Figure 5B). We varied kTB
p,V from 4
×1 0
-10 to 4 × 10
-4 cm/s. As kTB
p,V increases, free VEGF in
the normal tissue and blood plasma are relatively
unchanged (Figure 5B, top and middle panels). In com-
parison, upon increasing kTB
p,V, the concentration of
VEGF in the tumor decreases prior to the anti-VEGF
injection (Figure 5B, bottom panel). After the injection,
tumor free VEGF increases slightly with increasing kTB
p,V
Figure 5 Effect of systemic properties permeability. The concentration of free VEGF in the body following anti-VEGF treatment is predicted
for various parameter values. A, Microvascular permeability to VEGF between the normal tissue and blood. B, Microvascular permeability to VEGF
between the tumor and blood. C, Lymphatic flow from tumor to blood. From top to bottom: normal tissue (subscript N), blood (subscript B),
and tumor (subscript T). Bold in the legend indicates parameter value used in the current model.
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p,V is less than
10
-5 cm/s. These results indicate that making the tumor
vasculature more permeable to VEGF impedes the ther-
apeutic response to the anti-VEGF agent in the tumor.
Varying lymphatic drainage in the body does not pro-
duce noticeable changes in the VEGF distribution in the
body; however, the rate of lymph flow does impact the
distribution of free anti-VEGF and the VEGF/anti-VEGF
complex (Additional file 5). Increasing kL results in a
decrease in the concentration of free anti-VEGF and the
VEGF/anti-VEGF complex in normal tissue, while the
opposite trend is observed in the blood plasma and
tumor. The model predicts that increasing lymphatic
drainage allows the maximum amount of anti-VEGF to
be present in the blood and tumor compartments.
Although tumor lymphatics are non-functional, there
is evidence that normalization of the tumor vasculature
occurs with anti-VEGF treatment, interstitial pressure is
reduced, and lymphatics may become functional [51].
Therefore, we also investigated the effect of introducing
lymphatic flow from the tumor to the blood three weeks
after anti-VEGF treatment (Figure 5C). The effects of
allowing lymph drainage from the tumor is confined to
that particular compartment and results in a reduction
in tumor free VEGF that is distinct from the depletion
induced by the anti-VEGF. Thus, the model predicts
that if anti-VEGF therapy is able to restore tumor
lymph flow, the treatment has an additive effect of
further reducing tumor VEGF. Free VEGF in the tumor
decreases from 41 pM to 4.2 pM when kL is varied from
0t o6c m
3/min.
Properties of the anti-VEGF agent influence the
distribution of free VEGF in the body and impact the
response to treatment
Figure 6 shows how the concentration of free VEGF
changes in response to varying the permeability to the
anti-VEGF in the normal tissue and tumor (Figures 6A
and 6B, respectively), the rate of clearance of anti-VEGF
(Figure 6C), and the binding affinity of the anti-VEGF
to VEGF (Figure 6D). We varied the microvascular per-
meability to the anti-VEGF agent and the VEGF/anti-
VEGF complex in the normal tissue from 3 × 10
-11 to 3
×1 0
-5 cm/s, which induced changes in the distribution
of VEGF throughout the body. Increasing kNB
p,AV results in
a decrease in VEGF in the normal tissue following anti-
VEGF treatment (Figure 6A). Conversely, following
treatment, free VEGF in the tumor and blood both
increase as kNB
p,AV increases. Although tumor free VEGF
increases following treatment, the fold-change in free
VEGF is less than one for all values of kNB
p,AV examined,
indicating that the anti-VEGF agent induces the desired
therapeutic effect.
The permeability to anti-VEGF in the tumor has an
effect on the tumor compartment only (Figure 6B).
Increasing kTB
p,AV from 3 × 10
-10 to 3 × 10
-4 cm/s leads to
a decrease in free VEGF in the tumor from 74 pM to 43
pM at three weeks post-treatment. A therapeutic effect
is observed for the values of kTB
p,AV examined, with the
exception of kTB
p,AV on the order of 10
-10 cm/s. In that
case, the fold-change is only slightly greater than one.
The clearance of the anti-VEGF and the VEGF/anti-
VEGF complex influences the concentrations of these
species, as well as VEGF, in all compartments, as shown
in Figure 6C. We varied kc from 3.2 × 10
-10 to 3.2 × 10
-
4 s
-1, which changes the time it takes for the concentra-
tions of VEGF, anti-VEGF and the complex to return to
their steady-state values (see also Additional files 6 and
7). Larger values of kc cause the concentration of these
species to return to their steady-state values more
quickly. For example, when kc is 3.2 × 10
-4 s
-1,t u m o r
VEGF rebounds to its pre-treatment level within 4 days;
however, when kc is 3.2 × 10
-10 s
-1, tumor VEGF goes to
a pseudo steady-state and requires several weeks to
return to the pre-treatment level. Thus, increasing the
clearance rate for the anti-VEGF and VEGF/anti-VEGF
complex impedes the therapeutic action of the anti-
VEGF agent in the tumor.
The concentrations of VEGF, anti-VEGF, and the
VEGF/anti-VEGF complex in the body were sensitive to
the binding affinity of the drug to VEGF. Decreasing Kd
leads to a decrease in the concentration of free VEGF in
the tumor, where tumor VEGF decreases 4.2-fold when
Kd is varied from 0.022 pM to 22 nM. (Figure 6D).
Interestingly, for Kd<2.2 pM, the concentration of free
VEGF in all compartments immediately goes to nearly
zero until free anti-VEGF is cleared from the body
(Additional file 7), at which point free VEGF rebounds
to a new pseudo steady-state level within three weeks of
anti-VEGF treatment. The binding affinity also influ-
ences free anti-VEGF concentration and has a particu-
larly significant impact on the concentration of the
VEGF/anti-VEGF complex (Additional file 6). At Kd <
220 pM, the concentration of the complex in all com-
partments increases to approximately 600 μM.
At steady state, 22% and 13% of total VEGF in the
normal tissue and tumor, respectively, is sequestered by
the extracellular matrix (Additional file 4); however, it is
not known how anti-VEGF binding to matrix-bound
VEGF would influence the distribution of VEGF in the
body. The VEGF residues important for antibody bind-
ing and those responsible for receptor binding occupy a
common region [52]. Since the receptor-binding region
is distinct from the binding site for GAG chains in the
extracellular matrix, it is possible that the anti-VEGF
binds to matrix-bound VEGF. Therefore, we investigated
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sequestered in the extracellular matrix. The concentra-
tion profiles for VEGF, free anti-VEGF and the VEGF/
anti-VEGF complex when anti-VEGF can bind to VEGF
sequestered in the ECM are illustrated in Figure 7.
Allowing the anti-VEGF to bind to matrix-bound VEGF
influences the time required for VEGF concentration to
reach a pseudo-steady state after treatment; however,
the fold-change in free VEGF at three weeks post-treat-
ment is unaffected. The ability of the anti-VEGF to bind
matrix-bound VEGF does not therefore alter the pre-
dicted therapeutic effect. Approximately 90% of VEGF is
Figure 6 Effect of anti-VEGF properties. The concentration of free VEGF in the body following anti-VEGF treatment is predicted as properties
of the anti-VEGF are varied. A, Effect of microvascular permeability to anti-VEGF between the normal tissue and blood. B, Effect of microvascular
permeability to anti-VEGF between the tumor and blood. C, Effect of clearance rate of anti-VEGF and VEGF/anti-VEGF complex. D, Effect of anti-
VEGF binding affinity for VEGF. From top to bottom: normal tissue, blood, and tumor. Bold in the legend indicates parameter value used in the
current model.
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anti-VEGF treatment (Figure 8). As a result, the concen-
tration of the VEGF/anti-VEGF complex in the intersti-
tial space of the normal tissue and tumor is 13- and 7-
fold larger, respectively, when anti-VEGF binds matrix-
bound VEGF (Figure 7 compared to Figure 4, and Fig-
ure 8 compared to Additional file 4).
The effects of the systemic parameters and anti-VEGF
properties on the fold-change in free VEGF in the
tumor are summarized in Figure 9. As we have seen,
our model predicts how substantial changes in systemic
parameters and in pharmacokinetic and pharmacody-
namic parameters of the anti-VEGF agent influence the
concentration of free VEGF in the tumor following
administration of the anti-VEGF agent. Free VEGF in
the tumor is predicted to decrease following anti-VEGF
treatment for all of the parameters and ranges of para-
meter values examined in this study, with the exception
of kTB
p,V, the microvascular permeability to VEGF between
the tumor and blood. In this case, the model predicts
that when kTB
p,V is on the order of 10
-5 cm/s or larger,
free VEGF in the tumor increases following anti-VEGF
therapy. Thus, the therapeutic effect of the anti-VEGF is
robust and occurs for a wide range of values for sys-
temic parameters and drug properties.
Tumor-specific characteristics influence the response to
anti-VEGF treatment
We examined the role of the tumor microenvironment
and how tumor-specific characteristics influence the
response to anti-VEGF therapy. We first investigated the
effect of VEGF receptor expression on tumor cells. The
densities of VEGR1 and VEGFR2 were varied from 0 to
10,000 receptors/tumor cell, and the densities of NRP1
and NRP2 were varied from 0 to 100,000 receptors/
tumor cell. This study reveals the dependence of the
concentration of free VEGF in the body and the
response to anti-VEGF treatment on receptor expression
on tumor cells (Figure 10). There are combinations of
VEGF receptor densities for which tumor VEGF is pre-
dicted to decrease following intravenous injection of the
anti-VEGF agent, revealing the parameter space where
anti-VEGF treatment has a therapeutic effect. The fold-
change of tumor free VEGF in response to the
Figure 7 Effect of anti-VEGF binding matrix-bound VEGF. Concentration profiles following a single intravenous injection of 10 mg/kg anti-
VEGF given at time 0 when the anti-VEGF is able to bind matrix-bound VEGF. A, VEGF concentration. B, Anti-VEGF concentration. C, VEGF/anti-
VEGF complex concentration.
Figure 8 VEGF distribution with anti-VEGF binding matrix-
bound VEGF. VEGF distribution in the body. A, Normal tissue. B,
Blood. C, Tumor.
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and co-receptors. The threshold value for VEGFR1
expression needed to result in a therapeutic effect
depends on neuropilin expression. As the expression of
neuropilins increases, the level of VEGFR1 required to
result in a fold-change less than one in tumor free
VEGF decreases. The threshold value for the density of
VEGFR2 required to obtain a fold-change less than one
is approximately 7,000 receptors/tumor cell. The
instance where there are no NRPs on tumor cells is an
exceptional case, and the threshold values for VEGFR1
and VEGFR2 are 10,000 and 6,000 receptors/tumor cell,
respectively.
We next examined the rate of internalization of neu-
ropilin co-receptors to determine its effect on the
response to anti-VEGF therapy (Figure 11A). Neuropi-
lins greatly outnumber VEGFR1 and VEGFR2 in the
tumor and can form ternary complexes with VEGF and
VEGFR1 or VEGFR2. For these reasons, the availability
of neuropilins on the cell surface alters the dynamics of
anti-VEGF treatment. The model predicts that as the
rate of internalization of neuropilins increases from 2.8
×1 0
-6 to 2.8 × 10
-2 s
-1, the fold-change in free VEGF in
the tumor increases for neuropilin densities up to
80,000 molecules/tumor cell. There is a complex rela-
tionship between NRP internalization and the response
to anti-VEGF treatment when neuropilin density
exceeds about 80,000 molecules/tumor cell. In general,
as the internalization rate of neuropilins increases, the
therapeutic effect decreases, which is due to the com-
plex interactions between VEGF, neuropilins, and the
anti-VEGF. Decreasing NRP internalization leads to a
decrease in the rate at which VEGF is internalized due
to being bound to NRP1 or NRP2. As a result, VEGF
now has time to unbind from NRPs and subsequently
be sequestered by the anti-VEGF agent. These results
demonstrate that the anti-VEGF agent has an increased
therapeutic effect as the rate of NRP internalization
decreases.
Lastly, we examined the effect of VEGF secretion in
the tumor. As we show above, the isoform secretion
ratio influences the steady-state concentration of free
VEGF in the body (Figure 3B). Therefore, we sought to
understand the impact of the expression of VEGF iso-
forms on the response to anti-VEGF treatment. The iso-
form secretion ratio VEGF165:VEGF121 in the tumor was
varied between 100%:0% to 0%:100% from its current
value of 50:50%, while keeping the total VEGF secretion
rate constant. The isoform secretion ratio in normal tis-
sue remained at 92%:8%. As tumor VEGF secretion
includes more VEGF121, the fold-change decreases to
less than one (Figure 11B). Thus, a therapeutic effect is
observed when VEGF121 comprises at least 25% of the
total VEGF secreted from the tumor cells.
Discussion
We have developed a molecularly-detailed model of
VEGF transport in the body. This is the first human
model to include experimental measurements of recep-
tor densities as well as receptors on parenchymal cells,
and thus represents a significant advance compared to
previous models. By incorporating in vivo and in vitro
quantifications of VEGF receptor expression on
endothelial and parenchymal cells and experimentally-
Figure 9 Effect of systemic parameters and anti-VEGF properties on the response to anti-VEGF treatment. The fold-change in free VEGF
concentration following anti-VEGF treatment as a function of various model parameters. A, Systemic parameters. B, Anti-VEGF properties. Color
bar indicates range of values for each parameter, as given in Figures 5 and 6.
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Page 14 of 20Figure 10 Effect of receptor density on tumor cells. The fold-change in free VEGF concentration following anti-VEGF treatment is predicted
as a function of VEGFR1, VEGFR2, and neuropilin (NRP) expression. In all simulations, NRP1 = NRP2. A, NRP = 0 molecules/tumor cell. B, NRP =
5,000 molecules/tumor cell. C, NRP = 10,000 molecules/tumor cell. D, NRP = 15,000 molecules/tumor cell. E, NRP = 20,000 molecules/tumor cell.
F, NRP = 39,500 molecules/tumor cell. The white circle indicates receptor densities used in the current model: VEGFR1 = 1,100 molecules/tumor
cell, VEGFR2 = 550 molecules/tumor cell, NRP1 = NRP2 = 39,500 molecules/tumor cell. G, NRP = 80,000 molecules/tumor cell. H, NRP = 100,000
molecules/tumor cell. A-H, The gray dotted line in all panels is the isocline for a fold-change of 1.
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partments and VEGF secretion by tumors, we have cre-
ated a predictive tool that reflects physiological elements
of VEGF-mediated angiogenesis. Using the model, we are
able to predict how systemic properties, drug design
parameters, and properties of the tumor microenviron-
ment influence the response to anti-VEGF treatment.
Specifically, we have predicted the fold-change in free
VEGF following intravenous injection of an anti-VEGF
agent. Importantly, the model predicted that the outcome
of the anti-VEGF treatment (e.g., the level of free VEGF
in the tumor interstitium) is dependent on the tumor
microenvironment (e.g., receptor expression, internaliza-
tion of neuropilins, and VEGF isoform ratio) and there-
fore may vary from patient to patient or between groups
of patients. The model predicted that transport and bind-
ing parameters of the anti-VEGF can be fine-tuned such
that the drug acts to deplete free VEGF in the tumor.
Our model predicted that tight binding between the
anti-VEGF and VEGF results in a strong therapeutic
effect. Although free VEGF was reduced to nearly zero
in all compartments in the few hours following the
treatment, and the desired therapeutic effect is observed,
tight binding between VEGF and the anti-VEGF agent
may also induce adverse effects. The work of Gerber et
al. [53] shows a positive correlation between tight bind-
ing of the anti-VEGF to VEGF and the inhibition of
tumor growth; however, tighter association between
anti-VEGF and VEGF results in increased toxicity. Spe-
cifically, the authors identify renal changes that result
from increased antibody affinity, including glomerulo-
sclerosis and anti-VEGF deposition in glomeruli, as well
as hypoalbuminemia and ascites formation [53]. Further
investigation into the mechanism of glomerular injury
reveals that inhibition of VEGF in noncancerous tissues
such as the kidney results in a reduction of glomerular
Figure 11 Effect of tumor microenvironment on the response to the anti-VEGF treatment. The fold-change in free VEGF concentration
following anti-VEGF treatment is predicted as a function of properties of the tumor microenvironment. A, Effect of neuropilin internalization. B,
Effect of VEGF isoform-specific secretion.
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the adjacent microvasculature [54]. As VEGF is required
for cell maintenance and tissue homeostasis, inhibiting
endogenous VEGF signaling leads to additional side
effects [55]. Thus, there is an optimal value for the bind-
ing affinity where the anti-VEGF binds VEGF tightly
enough to inhibit tumor growth while limiting toxicity,
and this drug design parameter must be carefully
balanced with the occurrence of adverse events.
The occurrence of the desired therapeutic effect is
sensitive to the expression of VEGF receptors on tumor
cells. Our current model incorporates in vivo experi-
mental data for the density of VEGFR1 and VEGFR2
located on the normal and tumor endothelia, muscle
fibers (myocytes), and tumor cells. In contrast, the num-
ber of neuropilin receptors on various cell types has yet
to be quantified in vivo. Our analysis shows that the
occurrence of a therapeutic effect is dependent on the
density of VEGFRs and co-receptors. Therefore, accu-
rate estimates of neuropilin expression and the relative
density of NRP1 compared to NRP2 are required, as the
response to anti-VEGF therapy is sensitive to this prop-
erty of the tumor microenvironment.
In addition to the density of neuropilin expression on
tumor cells, the availability of these receptors also influ-
ences the response to anti-VEGF treatment. Since neu-
ropilins are co-receptors involved in angiogenesis and
are estimated to be present in large numbers on par-
enchymal cells, it is possible that the internalization of
these receptors may be dysregulated in pathological con-
ditions. Our model predicts that a low rate of internali-
zation of neuropilins leads to a more drastic reduction
of free VEGF in the tumor. A previous model was used
to compare therapeutic approaches of targeting NRP1
and shows that blocking NRP1 expression does not
result in persistent inhibition of VEGF signaling [56].
Our results support this finding, and in fact show that
prolonged expression of NRPs (inhibiting NRP internali-
zation) will improve the therapeutic effect of anti-VEGF
treatment. Teesalu and coworkers recently characterized
the amino acid motif of NRP1 that promotes its interna-
lization and found that blocking interaction at that site
inhibits internalization of the receptor [57]. Their work
suggests that it is possible to specifically target neuropi-
lin internalization.
The rate at which VEGF is secreted and the VEGF
isoform secretion ratio VEGF165:VEGF121 in the tumor
have a significant impact on the response to anti-VEGF
treatment and are crucial for prediction of the therapeu-
tic effect. Specifically, the rate of VEGF secretion in the
tumor can be used to tune the steady-state level of free
VEGF in the tumor and influences whether an anti-
VEGF agent works to deplete tumor VEGF. Our model
predicts that the steady-state concentration of tumor
free VEGF prior to treatment influences whether the
anti-VEGF has a therapeutic effect. This underscores the
need for isolation of tumor interstitial fluid and mea-
surement of its VEGF concentration, which may be used
as a predictive biomarker for administration of specific
anti-angiogenic drugs and serve in stratification of
patients who would best respond to a specific therapy.
Similarly, there is a need for quantitative measure-
ments of the relative secretion of VEGF isoforms. These
data would aid in refining the model and would lead to
a better understanding of the effects of drugs that target
VEGF-mediated angiogenesis. It is interesting to note
that the VEGF isoform ratio in tumor tissues is in the
range required for an anti-VEGF agent to have a thera-
peutic effect, as compared to the ratio observed in other
tissues such as muscle. These results bring into question
whether the VEGF isoform expression may be a useful
biomarker to predict a therapeutic response to anti-
VEGF treatment.
We have shown that the properties of the tumor
should be taken into account when developing treat-
ment strategies. It would be of interest to predict the
effect of anti-VEGF treatment when using receptor
quantification and the relative secretion of VEGF iso-
forms for specific types of tumors. This type of analysis
may provide insight as to why certain tumors respond
to anti-VEGF treatment better than others. Additionally,
the incorporation of tumor-specific properties is
required to develop personalized medicine and identify
the patient population that is best-suited for VEGF-tar-
geted therapies [58].
Our model of VEGF distribution is used to investigate
the effect of anti-VEGF agents in targeting VEGF and
inhibiting angiogenesis. An alternative or complemen-
tary view is that the anti-VEGF therapy works through
vascular normalization, i.e., repairing tumor vasculature
to resemble normal vessels, leading to increased pericyte
coverage and increased blood perfusion, reduced inter-
stitial pressure, and tightened endothelial cell junctions
[51]. Clinically, metastasis is reduced and the efficacy of
chemo-, radiation- and immune-therapies is improved
upon vessel normalization [7]. Interestingly, our model
predicts that when tumor lymphatics become functional,
perhaps due to a reduction in interstitial pressure fol-
lowing normalization, the anti-VEGF has a more potent
therapeutic effect. Similarly, it would be of interest to
incorporate the dynamic effects of vascular normaliza-
tion on macromolecular permeability, which is reduced
following normalization, in order to understand how
this influences the response to anti-VEGF therapy. Vas-
cular normalization is a transient response, character-
ized by an optimal time window after which the
normalized features of the tumor vasculature are lost,
possibly due to prolonged anti-VEGF treatment or
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current model predicts that tumor VEGF is immediately
reduced following anti-VEGF treatment and then
rebounds to a new pseudo-steady state below pre-treat-
ment levels within 7 days. The time it takes for tumor
VEGF to rebound may correspond to the normalization
window. Therefore, our model can be used to explore
how the duration of the normalization window depends
on systemic and drug parameters and tumor properties.
Several assumptions influence the model predictions
and should be re-evaluated as quantitative experimen-
t a ld a t ab e c o m ea v a i l a b l e .W eh a v ea s s u m e de q u a ld i s -
tribution of receptors on the luminal and abluminal
surface of endothelial cells. Previous work predicts that
quantification of luminal and abluminal receptors
influences VEGF distribution in the body [34]. We
have assumed that the total number of receptors is
conserved; however receptor expression is a dynamic
process and the cell-surface receptor density might
depend on VEGF concentration among other factors
[31]. Additionally, the administration of an anti-VEGF
agent may affect receptor expression over days and
weeks, the time scale investigated in the present study.
Therefore, incorporating receptor dynamics and quan-
tifying the effect of anti-VEGF therapy on receptor
density would better reflect biological conditions. Anti-
VEGF therapies influence the tumor vasculature and
may also have anti-tumor effects leading to tumor
growth inhibition. However, we have assumed that the
size of the tumor remains constant throughout the
model simulation. It would be of interest to incorpo-
rate a function for tumor growth and/or regression as
a function of time. Lastly, the effects of platelet con-
tent or the ability of platelets to secrete and sequester
angiogenic proteins has not been addressed. Since
degranulation of platelets is a source of VEGF and pla-
telets have been shown to sequester the VEGF anti-
body bevacizumab [60], it is important to add platelets
to the model.
Conclusions
The model predicted that the therapeutic response to
anti-VEGF treatment is robust across a large range of
systemic and drug parameter values. However, proper-
ties of the tumor microenvironment such as receptor
expression and availability and VEGF isoform secretion
ratio significantly influence the response to anti-VEGF
therapy. Our results are important in elucidating effects
of drug design and tumor-specific parameters that are
difficult to predict a priori and may be helpful in opti-
mizing VEGF-neutralizing drugs.
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B, Effect of NRP2 coupling to VEGF165/VEGFR2. C, Effect of VEGF165/NRP2
coupling to VEGFR2. D, Effect of NRP2 coupling to VEGFR1. In all panels,
gray circles indicate baseline values taken from NRP1 interactions.
Additional file 3: Comparison of the concentration of free VEGF in
the tumor interstitial space calculated from experimental data and
based on model predictions.
Additional file 4: VEGF distribution following a single intravenous
injection of 10 mg/kg of anti-VEGF given at time 0. A, normal tissue,
B, blood, and C, tumor.
Additional file 5: The concentration profiles for A, free VEGF; B, free
anti-VEGF; and C, the VEGF/anti-VEGF complex are predicted as the
lymphatic flow rate from the normal tissue to the blood was varied.
From top to bottom: normal tissue, blood, and tumor. The lymph flow
rate influences the concentration of the anti-VEGF and VEGF/anti-VEGF
complex. Legend in A applies to all panels; bold in the legend indicates
the parameter value used in the current model.
Additional file 6: The concentration of the VEGF/anti-VEGF complex
in the body following anti-VEGF treatment is predicted as
properties of the anti-VEGF are varied. A, Effect of microvascular
permeability to anti-VEGF between the normal tissue and blood. B, Effect
of microvascular permeability to anti-VEGF between the tumor and
blood. C, Effect of clearance rate of anti-VEGF. D, Effect of anti-VEGF
binding affinity to VEGF. From top to bottom: normal tissue, blood, and
tumor. Bold in the legend indicates parameter value used in the current
model.
Additional file 7: The concentration of free anti-VEGF in the body
following anti-VEGF treatment is predicted as properties of the
anti-VEGF are varied. A, Effect of microvascular permeability to anti-
VEGF between the normal tissue and blood. B, Effect of microvascular
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clearance rate of anti-VEGF. D, Effect of anti-VEGF binding affinity to
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